(Q41190113)

28 September 2017

1 reference

title

PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis (English)

1 reference

28 September 2017

0 references

Stewart AF

1

1 reference

28 September 2017

publication date

1 October 1996

1 reference

28 September 2017

1 reference

28 September 2017

volume

19

1 reference

28 September 2017

issue

4

1 reference

28 September 2017

page(s)

303-306

1 reference

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Defining the roles of parathyroid hormone-related protein in normal physiology

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Skeletal disease in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900221-9

7 January 2021

10.1016/S8756-3282(96)00221-9

Identifiers

DOI

1 reference

28 September 2017

1 reference